Your browser doesn't support javascript.
loading
CCL5 Release by CCR9+ CD8 T Cells: A Potential Contributor to Immunopathology of Primary Sjögren's Syndrome.
Hinrichs, Anneline C; Blokland, Sofie L M; Kruize, Aike A; Lafeber, Floris P J; Leavis, Helen L; van Roon, Joel A G.
Affiliation
  • Hinrichs AC; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Blokland SLM; Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Kruize AA; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Lafeber FPJ; Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Leavis HL; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • van Roon JAG; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Front Immunol ; 13: 887972, 2022.
Article in En | MEDLINE | ID: mdl-35720379
ABSTRACT

Introduction:

Increased CCL5 expression and CD8 T cells have been shown to be pivotal regulators of immunopathology in primary Sjögren's syndrome (pSS) and pSS-like disease. Increased CCL5 expression by CCR9+ CD4 T cells has previously been implicated as a contributor to immunopathology in pSS. The role of CD8 T cells and in particular CCR9+ CD8 T cells and their potential to secrete CCL5 has not previously been studied in pSS. In this study we investigated both CCR9 and CCL5 expression by CD8 T cells in pSS patients compared to healthy controls (HC).

Methods:

CCR9 expression on CD8 T cells from peripheral blood was compared between patients with pSS and HC by flow cytometry. Intracellular CCL5 expression by naive, memory and effector CCR9- and CCR9+ CD8 T cells was assessed. In addition, the capacity and pace of CCL5 release upon T cell activation was determined for all subsets and compared with CD4 T cells.

Results:

The frequency of circulating CCR9+ CD8 T cells in pSS patients is increased compared to HC. Antigen-experienced CD8 T cells, especially CCR9+ effector CD8 T cells, express the highest CCL5 levels, and release the highest levels of CCL5 upon activation. Memory and effector CD8 T cells of pSS patients express significantly less CCL5 and subsequently release less CCL5 upon stimulation compared to HC. CCR9+ CD8 T cells rapidly release CCL5 and significantly more than CCR9+ CD4 T cells.

Conclusion:

CCR9+ CD8 T cells express more CCL5 than CCR9- CD8 T cells. CCL5 is rapidly released upon activation, resulting in reduced intracellular expression. Reduced CCL5 expression by an elevated number of antigen-experienced CCR9-expressing CD8 T cells in pSS patients points towards increased release in vivo. This suggests that CCL5 release by CCR9+ CD8 T cells contributes to immunopathology in pSS.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sjogren's Syndrome / CD8-Positive T-Lymphocytes / Chemokine CCL5 / Receptors, CCR Limits: Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sjogren's Syndrome / CD8-Positive T-Lymphocytes / Chemokine CCL5 / Receptors, CCR Limits: Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country:
...